Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Brit and Japanese scientists share Nobel Prize for 'groundbreaking' stem cell work that 'revolutionised' science
Sir John Gurdon, 79, shared the Nobel Prize with Japan's Shinya Yamanaka for their 'groundbreaking work' that has revolutionised science', the Nobel Assembly at Sweden's Karolinska Institute.
Gladstone researchers say the discovery could have a profound impact on how we treat hearts and heart disease.
Retired Senior Investigator Karl Weisgraber has had a long, difficult recovery from a fall off a ladder that caused a traumatic brain injury last October.
Gladstone investigators Eric Verdin, MD, and Shomyseh Sanjabi, PhD, are researching why patients living with HIV are aging prematurely.
Scientists at the Gladstone Institutes have created the first "genomic blueprint" of the human heart, unveiling the exact order and timing of genetic events that must take place for an embryonic heart cell to become a beating, life-sustaining organ.
Scientists led by a team at the Gladstone Institutes are getting closer to understanding how much antiretroviral medication people need to take to protect themselves from being infected with HIV.
Reasearchers from Gladstone Institutes in California have created a blueprint map of how the heart developes in time.
Using stem cell technology, next-generation DNA sequencing and computer tools, researchers at the Gladstone Institutes in California, and other academic centers, have mapped how a heart becomes a heart.
Truvada, the only medication approved by the U.S. Food and Drug Administration for HIV prevention, is effective in blocking the virus even if people do not adhere to their daily regimen perfectly, a new study indicates.
Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.